fda removes semaglutide shortage list 2025 ends as sets deadline for compounders FDA Announces End to Semaglutide

Norfold, G

Get clinical support from providers who understand metabolic medicine not just GLP-1 prescribing

Self-monitoring of blood glucose becomes particularly important during the transition period

Clients who have a history of the following SHOULD NOT take Semaglutide:: Type I diabetes A history of pancreatitis (inflammation of the pancreas) Active suicidal thoughts A history of allergic reaction to any of the components of semaglutide A personal or family history of medullary thyroid carcinoma A personal or family history of multiple endocrine neoplasia syndrome type 2 (MEN2) Patients who are currently pregnant, may become pregnant, or breastfeeding

We also offer more than one path: This is still medicine

Emerging platforms, including curcuminoid-piperine co-formulations, phospholipid complexes, polymeric nanoparticles, and micellar systems, may substantially improve systemic exposure and therapeutic reproducibility